Plate Nº 15 · recorded October 10, 2026
Health & Medicine ResearchReported finding
UCSF team uses CRISPR to reprogram immune cells inside the body
UCSF researchers report in Nature that a CRISPR two-particle system made leukemia vanish in nearly all treated mice within two weeks — the first targeted DNA insertion in human T cells without removing them.
By Elena Vasquez3 min read658 words
In brief
- The Nature paper was published on October 7, 2026.
- A single injection of the therapy wiped out detectable leukemia in nearly all treated mice within 14 days.
- Engineered CAR-T cells accounted for up to 40% of all immune cells in some organs of treated mice.
- Existing CAR-T therapies cost between $400,000 and $500,000 per patient.
- Seven CAR-T therapies are currently approved by the U.S. Food and Drug Administration.
How could the cost and wait for CAR-T therapy fall?
In a paper published October 7, 2026, in Nature, scientists at UC San Francisco reported that a single injection of a CRISPR-based therapy made all detectable leukemia disappear in nearly all treated mice within two weeks. The work is the first to insert a long DNA segment into a precise spot in human T cells without first removing those cells.
CAR-T therapy works by giving T cells, the immune system's main attackers, new genetic instructions to make chimeric antigen receptors (CARs). These receptors sit on the cell surface like antennae and latch onto a specific protein on cancer cells, triggering an attack. Seven such treatments are currently approved by the U.S. Food and Drug Administration for blood cancers.
Yet reaching patients remains hard:
- Each therapy costs between $400,000 and $500,000.
- Manufacturing takes weeks at specialized facilities.
- Patients usually receive intensive chemotherapy first.
"It's become a global access issue; many patients who would benefit from CAR-T cells either can't afford them or can't get them fast enough," said Justin Eyquem, PhD, an associate professor of medicine at UCSF and the senior author of the new study.
How does the new system deliver CAR instructions inside the body?
Eyquem's team, working with collaborators at the Gladstone Institutes, Duke University, and the Innovative Genomics Institute, built a two-particle platform that homes in on T cells circulating in the bloodstream.
The first particle carries CRISPR-Cas9, the molecular scissors that cut DNA. Its surface is coated with antibodies recognizing CD3, a protein found only on T cells. That targeting system steers the gene-editing tools toward the right cells.
The second particle delivers the DNA coding for the cancer-fighting CAR. It also carries signals that guide CRISPR to a precise spot in the T cell genome where a molecular "on switch" operates only in T cells. The new gene therefore switches on only after it lands in the right place.
The researchers also designed the particles to resist rapid destruction by the immune system. Without the lab-based quality checks that conventional CAR-T manufacturing relies on, Eyquem's team had to tune the platform carefully upfront to avoid editing cells outside the intended T cell population.
What did the mouse experiments show?
Co-first authors William Nyberg, PhD, and Pierre-Louis Bernard, PhD, both UCSF postdoctoral fellows, tested the platform in mice carrying aggressive human leukemia. A single injection wiped out cancer in nearly every animal within 14 days. In some organs, the engineered CAR-T cells made up 40% of all immune cells, and the treatment also cleared bone marrow and spleen.
The same strategy beat back multiple myeloma and a solid sarcoma tumor, an outcome CAR-T has historically struggled to achieve in solid cancers. The team also noticed an unexpected bonus: T cells engineered inside the body outperformed lab-grown versions, possibly because removing cells and culturing them strips away some "stemness" and proliferative capacity.
What still needs to happen before patients see this?
The technology is not ready for clinical use. Researchers must scale up production, and human trials will need to confirm safety and effectiveness.
Eyquem and his collaborators have founded Azalea Therapeutics to advance the dual-particle platform toward those trials. If the approach succeeds in people, it could collapse the current weeks-long, multi-step pipeline into a single injection given at community hospitals.
"If we can translate this to humans, we could dramatically reduce costs, eliminate waiting times, and potentially allow community hospitals — not just major cancer centers — to offer these life-saving therapies," Eyquem said. "That would truly democratize access to CAR-T cell therapy."
The targeted insertion technique also beat the conventional virus-based approach, which scatters DNA randomly through the genome. That broader edge suggests the method could reshape cell and gene therapies well beyond cancer.
via dx.doi.org (Original)
More from Elena Vasquez
Nearby plates
- Updated CAR T-Cell Therapy Guidance Targets Severe Autoimmune Diseases
- CRISPR-edited stem cells engrafted in all 30 patients in blood cancer trial
- Only 14% of U.S. CAR-T trials accept HIV-positive cancer patients
- Nanoparticles flag and destroy hidden glioblastoma cells in mice
- Same-Day Chemotherapy Turns Into a Booster for Cancer Vaccines